Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Amazon Explores AI Content Marketplace With Media Publishers 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
CAMBRIDGE, Mass., Nov. 13, 2017 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced management presentations at the upcoming investor conferences:
- Stifel 2017 Healthcare Conference, New York City
Date: Wednesday, November 15, 2017
Time: 2:00 p.m. EST
Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer
- Piper Jaffray Healthcare Conference, New York City
Date: Tuesday, November 28, 2017
Time: 9:00 a.m. EST
Panel Members: Jane Henderson, chief financial officer and senior vice president of corporate development and Bernard Ravina, M.D., M.S., chief medical officer - Evercore ISI Biopharma Catalyst/Deep Dive Conference, Boston, MA
Date: Wednesday, November 29, 2017
Time: 3:30 p.m. EST
Panel Members: Steven Paul, M.D., president and chief executive officer and Jane Henderson, chief financial officer and senior vice president of corporate development
Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days after the live event concludes.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.
Investor Relations:
Matt Osborne
Vice President of Investor Relations & Corporate Communications
857-259-5353
[email protected]
Media:
Katie Engleman
Pure Communications, Inc.
910-509-3977
[email protected]
